Abstract
Umbilical cord blood is a unique source of hematopoietic cells for transplantation in hematological diseases and other socially significant pathologies. The development of regenerative medicine requires clear protocols governing the use of umbilical cord blood and its components (cells, plasma) in clinical practice. In the Russian Federation, today, there is no proper regulatory framework for working with umbilical cord blood and its components, which is a limiting factor in the development of cellular technologies and regenerative medicine in general. The article analyzes the legal framework for regulating the use of umbilical cord blood and its components in the Russian Federation and abroad - the countries of the European Union and America.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
